Close Menu

NEW YORK – Whole-genome sequencing may be a practical method for finding markers to guide treatment in metastatic cancer patients, new research suggests.

At the European Society for Medical Oncology's Virtual Congress on Saturday, pathologist Kim Monkhorst from the Netherlands Cancer Institute shared interim results for the first 800 of the 1,200 patients who will be profiled through the "Whole-genome sequencing implementation and standard of care diagnostics for every cancer patient," or WIDE, study.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
LGC SeraCare Life Sciences

This webinar features a panel of industry stakeholders in cancer diagnostics, proficiency testing and clinical care who will discuss the promise and challenges of liquid biopsy technologies in disease diagnosis, monitoring, and patient care management.


Illumina’s BaseSpace Sequence Hub (BSSH) supports primary and secondary analysis of massively parallel sequencing data and can be applied to gene panel data that is generated as part of a clinical cancer assay performed in a pathology lab.


Molecular tumor profiling has provided extensive value, both in tumor biology and oncology, with the development of new technologies to identify biomarkers.

Sponsored by
Akoya Biosciences

Most recent single-cell and spatial biology studies have focused on the network of interactions between different cell types and their spatial context.